XiFin, a company specializing in revenue cycle management (RCM) and billing solutions enhanced with embedded artificial intelligence (AI), announced a new growth capital investment alongside the appointment of health IT innovator Jeff Margolis to its Board of Directors. This funding round builds on XiFin’s 19% year-over-year growth, largely driven by client adoption of its flagship platform, XiFin® Empower.
The investment was co-led by Goldman Sachs External Investing Group, with additional funding from majority investor Avista Healthcare Partners and other institutional investors. Financial terms of the investment were not disclosed.
Erik Sallee, Chief Financial Officer at XiFin, commented on the development, stating that “XiFin is uniquely positioned to capitalize on an inflection point in the industry, with AI presenting a once-in-a-generation opportunity to modernize RCM.” He added that the support from investors provides “excellent financial flexibility to continue solving complex healthcare challenges and delivering industry-leading technology to more partners.”
This growth capital supports strong demand for XiFin’s technology infrastructure, which unifies automation, data analytics, and AI to streamline revenue cycle workflows, improve financial performance, and enhance the patient and provider experience. Designed with real-time data exchange and interoperability, XiFin Empower RCM connects patients, healthcare and pharmaceutical providers, and payors across the health ecosystem, aiming to extend medical providers’ operational and clinical reach.
Marc Boheim, Head of Co-Investments at Goldman Sachs External Investing Group, reinforced the investment’s significance. “Our growth capital commitment underscores a strong conviction in XiFin and the critical role its industry-leading technology plays in modernizing healthcare RCM,” Boheim said. He noted the company’s “impressive trajectory of value creation, both organically and through acquisitions, as providers turn to trusted platforms like XiFin Empower RCM to help navigate the care delivery life cycle.”
In addition to the funding, XiFin’s Board of Directors will benefit from the expertise of Jeff Margolis, a healthcare information technology veteran with over 35 years of experience in AI innovation. Margolis previously founded TriZetto, an early vertical SaaS platform in the industry providing benefit plan administration solutions that served over 130 million people.
Currently, Margolis serves as a Senior Advisor to Blackstone and as a board member for various companies, advising on strategic investments and advancing healthcare and IT innovation. He is also the author of several books on healthcare. Margolis expressed enthusiasm for his new role, stating, “XiFin is supporting America’s healthcare providers—from hospitals and health systems, to pharmacies, ancillary and diagnostic services, to pharmaceutical companies—with solutions that unite a disconnected ecosystem, redefine RCM, and maintain focus on patient care.” He looks forward to collaborating with XiFin’s management team to help providers leverage proprietary AI solutions for increased efficiencies and stakeholder benefits.
XiFin is a healthcare information technology company that uses AI-enabled technologies and services through its XiFin Empower platform to deliver operational efficiency, increased productivity, and workflow automation. Its solutions encompass revenue cycle management, clinical workflow enablement, laboratory information systems, and patient engagement.
Avista Healthcare Partners, established in 2005, is a New York-based private equity firm that has invested over $10 billion in 50 growth-oriented healthcare businesses globally. The firm focuses on healthcare product and technology businesses with strong management teams, stable cash flows, and robust growth prospects.
Goldman Sachs External Investing Group manages over $500 billion in assets and has more than 30 years of experience in alternative investments globally, including private equity, growth equity, private credit, and other sectors.
